- Home
- VINP vs ANAB Comparison
VINP vs ANAB Comparison
Compare VINP & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINP
- ANAB
- Stock Information
- Founded
- VINP 2009
- ANAB 2005
- Country
- VINP Brazil
- ANAB United States
- Employees
- VINP N/A
- ANAB N/A
- Industry
- VINP Investment Managers
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- VINP Finance
- ANAB Health Care
- Exchange
- VINP Nasdaq
- ANAB Nasdaq
- Market Cap
- VINP 593.2M
- ANAB 621.1M
- IPO Year
- VINP 2021
- ANAB 2017
- Fundamental
- Price
- VINP $9.51
- ANAB $22.47
- Analyst Decision
- VINP Strong Buy
- ANAB Buy
- Analyst Count
- VINP 2
- ANAB 10
- Target Price
- VINP $13.25
- ANAB $44.25
- AVG Volume (30 Days)
- VINP 47.4K
- ANAB 661.9K
- Earning Date
- VINP 08-06-2025
- ANAB 08-04-2025
- Dividend Yield
- VINP 6.75%
- ANAB N/A
- EPS Growth
- VINP N/A
- ANAB N/A
- EPS
- VINP 0.38
- ANAB N/A
- Revenue
- VINP $126,696,258.00
- ANAB $111,872,000.00
- Revenue This Year
- VINP $70.28
- ANAB N/A
- Revenue Next Year
- VINP $14.37
- ANAB $24.39
- P/E Ratio
- VINP $25.30
- ANAB N/A
- Revenue Growth
- VINP 57.51
- ANAB 387.20
- 52 Week Low
- VINP $8.66
- ANAB $12.21
- 52 Week High
- VINP $11.62
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- VINP 47.61
- ANAB 49.83
- Support Level
- VINP $9.41
- ANAB $22.49
- Resistance Level
- VINP $9.70
- ANAB $24.86
- Average True Range (ATR)
- VINP 0.23
- ANAB 1.27
- MACD
- VINP 0.01
- ANAB -0.17
- Stochastic Oscillator
- VINP 43.48
- ANAB 10.49
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).